These 28 biotech startups have attracted the most VC cash — making them prime candidates for either an acquisition or an IPO

Venture capital money flowing into biotech over the last few years has led to record levels of private financings, according to a new analysis by Jefferies analyst Michael Yee and his team.  Based on industry trends, companies with funding rounds in the last two years could go public next year or in 2021, they said. Those companies could also be targets for M&A.  Read on to see the companies with the top 30 fundraising

Continue reading...